万春医药上涨2.5%，报2.05美元/股，总市值8266.08万美元

Core Insights - BeyondSpring Pharmaceuticals (BYSI) opened with a 2.5% increase, reaching $2.05 per share, with a total market capitalization of $82.66 million as of 21:30 [1] - For the fiscal year ending June 30, 2024, the company reported total revenue of $1.00 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.26 million, showing a 42.91% increase in losses compared to the previous year [1] Company Overview - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [1] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers, targeting areas such as non-small cell lung cancer and the prevention of neutropenia [1] Business Model and Strategy - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1] - The company's research focus includes Plinabulin in combination with PD-1 monoclonal antibodies [1]